Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43DC.A.TO 0.3NESN-SIX 0MCK 31.3
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Nov 20, 2007
(All 3 Top Picks are defensive, have good dividends, solid earnings and limited downside.) 5% yield and will probably raise the dividend. About $19 billion cash for acquisitions. Drugs that are coming off patent is already built into the stock.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.72

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 01, 2007
(A Top Pick Dec 21/06. Down 5.6%.) The model price is $42.64, giving it a 73% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.95

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 23, 2007
Has taken it's licks. If they prevail on their lawsuits on their patents then they will go up. He likes the generics more then the big R & D houses.
Photo of David BaskinDavid BaskinUnlock Rating
$23.98

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 16, 2007
Trading at a very attractive multiple (less then 10X next years earnings), 4.5% dividends. They have a lot of things going on in the pipeline. Must be patient with this though.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$24.63

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 10, 2007
His model price is $42.32 a positive 66% differential. Until they read off their goodwill, the stock will probably be in the doghouse for a while.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.54

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 11, 2007
This is a value stock. A number of its drugs have either come off patent or will be in the next 2, 3 years. On the other hand, it has a strong research/development pipeline and about $19 billion in cash. Cash will be used to raise the dividends, buy back
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.19

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 10, 2007
Many pharmaceuticals are faced with an uncertain political environment. This is more important than patent expirations. They are faced with a national health system in the US if there is a change in the government in 2008.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CIC
No
Unlock Rating
$23.96

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 29, 2007
You are getting almost 5% yield while waiting for their pipeline to improve. All the bad news about drugs coming off of patent is out now. Have a huge cash horde that they will use at the right time to acquire companies with promising drugs.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.67

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
BUY

Pfizer Inc(PFE)

Aug 22, 2007
His model price is $39.86, a 61% positive differential. In his top 10. The one consolation on this is that you get a 5% dividend while you wait. Hopes they will write off a lot of their Pharmacia acquisition. Until they do, he doesn't expect much movement.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.65

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 16, 2007
Almost 5% yield. Their cholesterol drug is coming off patent, which almost made up 25% of their revenues. They have to find a way to replace this.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$23.39

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 15, 2007
Corrected partly because of the market and also its latest earnings report was somewhat disappointing even though the company advised that the full year and next year's earnings are expected to be as they previously stated. Almost 5% yield, which totally limits downside risk in the stock. On a market turn around, this will be a major participant.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.53

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jul 27, 2007
(A Top Pick July 21/06 Up 1%.) Pays a 5% dividend. His model price is $41.35, a 71% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.79

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 24, 2007
Has been a very frustrating stock to have. Doesn't seem to be able to get out of its own way.
Photo of Brendan CaldwellBrendan Caldwell
Owned
Unlock Rating
$24.89

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 18, 2007
Just reported numbers that were a little bit lighter than expectations. They also reaffirmed their view for next year that they expect to make back the shortfall later in the year. This knee-jerk reaction is an opportunity. 4.5% new.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.13

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 17, 2007
Doesn't like the business models of pharmaceutical companies. Can be hit by generics, lawsuits, etc.. Prefers business models with downside protection. After the next US election, expect there will be severe regulations on pharmaceutical prices.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$25.96

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 556 to 570 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.89$313.23
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.71$53.29

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.79$96.32
U.U.TO 0.5$20.92
SII.TO 2.94$190.13
IPCO.TO -0.43$34.79

Popular Articles

Latest Sell Signals

RKLB -1.37$66.91
INTC 0.22$87.48
MSFT 4.4$491.71
WSP.TO -2.98$189.3
CLS.TO 16.21$423.57

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like